Oliva, Marc http://orcid.org/0000-0001-5352-8130
Schneeberger, Pierre H. H. http://orcid.org/0000-0002-8586-4937
Rey, Victor
Cho, Matthew
Taylor, Rachel
Hansen, Aaron R.
Taylor, Kirsty
Hosni, Ali
Bayley, Andrew
Hope, Andrew J.
Bratman, Scott V.
Ringash, Jolie
Singh, Simron
Weinreb, Ilan
Perez-Ordoñez, Bayardo
Chepeha, Douglas
Waldron, John
Xu, Wei
Guttman, David
Siu, Lillian L. http://orcid.org/0000-0002-3500-0540
Coburn, Bryan
Spreafico, Anna http://orcid.org/0000-0002-3034-3042
Article History
Received: 31 May 2020
Revised: 25 November 2020
Accepted: 17 December 2020
First Online: 10 March 2021
Ethics approval and consent to participate
: ROMA LA-OPSCC-001 was a prospective observational study that only involved the collection and analysis of saliva, oropharyngeal swabs and stool samples and did not determine the eligibility to receive treatment. The study was approved by the Princess Margaret Cancer Centre Institutional Research Ethics Board (Study ID 17-5693) and was conducted in accordance with the Declaration of Helsinki. All patients provided written, signed, informed consent to participate.
: Not applicable.
: The data sets generated and/or analysed during the current study are not yet publicly available but are available from the corresponding author on reasonable request.
: M.O.: consultant for: Bristol-Myers Squibb Canada (compensated), Mirati Therapeutics. Speaker’s Bureau for: None. Employee of: None. Grant/Research support from (Clinical Trials): Mirati Therapeutics, Nubyota. L.L.S.: Consultant for: Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca/Medimmune (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus (compensated), Symphogen (compensated), Seattle Genetics (compensated), GSK (compensated), Voronoi (compensated), Treadwell Therapeutics (compensated). Speaker’s Bureau for: None. Grant/Research support from (Clinical Trials for institution): Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks, Avid. Stockholder in: Agios (spouse). Employee of: None. A.S.: consultant for: Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), Oncorus (compensated). Speaker’s Bureau for: None. Grant/Research support from (Clinical Trials): Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Array Biopharma. Stockholder in: None. Employee of: None. All of the other authors declare that they have no competing interests.
: This study was partly supported by M.O.’s ASCO Conquer Cancer Foundation Young Investigator Award (YIA) 2019 and by A.S.’s Division of Medical Oncology, Department of Medicine, University of Toronto Strategic Planning Innovation Grant. M.O.’s fellowship program to conduct the ROMA LA-OPSCC study was supported by the Spanish Society for Medical Oncology Foundation (FSEOM)/Fundación Cris Contra el Cáncer Grant and by the Princess Margaret Cancer Centre Head & Neck Discovery Program. P.H.H.S. fellowship was partly supported by the Tomcyzk AI and Microbiome Working Group and The Princess Margaret Cancer Foundation.